Microbiota Control of Malaria Transmission

Trends in Parasitology

Volumn 32, Issue 2, 2016, Pages 120-130

  Soares, Miguel P ^a   Yilmaz, Bahtiyar ^a,b  

^a INSTITUTO GULBENKIAN DE CIÊNCIA   (Portugal)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; BACTERIUM LIPOPOLYSACCHARIDE; GLYCAN; IMMUNOGLOBULIN G; ANTIBODY; POLYSACCHARIDE; PROTOZOAL VACCINE;

ANOPHELES; B LYMPHOCYTE; BACTERIAL COLONIZATION; BLOOD GROUP; CELL MATURATION; CELL MEDIATED CYTOTOXICITY; COMPLEMENT CLASSICAL PATHWAY; GENE CONTROL; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; INTESTINE FLORA; KLEBSIELLA PNEUMONIAE; LOSS OF FUNCTION MUTATION; MALARIA CONTROL; MICROFLORA; NONHUMAN; PARASITE TRANSMISSION; PLASMODIUM; REVIEW; SALMONELLA ENTERICA SEROVAR MINNESOTA; SALMONELLA ENTERICA SEROVAR TYPHIMURIUM; SHIGELLA DYSENTERIAE; SYMBIOSIS; TRYPANOSOMA BRUCEI; TRYPANOSOMA CRUZI; EVOLUTION; IMMUNOLOGY; INTESTINE; MALARIA, FALCIPARUM; MICROBIOLOGY; PHYSIOLOGY; PLASMODIUM FALCIPARUM; TRANSMISSION;

ANTIBODIES; BIOLOGICAL EVOLUTION; HOST-PATHOGEN INTERACTIONS; HUMANS; INTESTINES; MALARIA, FALCIPARUM; MICROBIOTA; PLASMODIUM FALCIPARUM; POLYSACCHARIDES; PROTOZOAN VACCINES;

EID: 84959139701     PISSN: 14714922     EISSN: 14715007     Source Type: Journal    
DOI: 10.1016/j.pt.2015.11.004     Document Type: Review

References (95)

1. Lozupone C.A., et al. Diversity, stability and resilience of the human gut microbiota. Nature 2012, 489:220-230.
2. Marchiando A.M., et al. Epithelial barriers in homeostasis and disease. Annu. Rev. Pathol. 2010, 5:119-144.
3. Rakoff-Nahoum S., et al. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004, 118:229-241.
4. Macpherson A.J., et al. The bilateral responsiveness between intestinal microbes and IgA. Trends Immunol. 2015, 36:460-470.
5. Hooper L.V., Macpherson A.J. Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat. Rev. Immunol. 2010, 10:159-169.
6. Palm N.W., et al. Immunoglobulin A coating identifies colitogenic bacteria in inflammatory bowel disease. Cell 2014, 158:1000-1010.
7. Yilmaz B., et al. Gut microbiota elicits a protective immune response against malaria transmission. Cell 2014, 159:1277-1289.
8. Kearney J.F., et al. Natural antibody repertoires: development and functional role in inhibiting allergic airway disease. Annu. Rev. Immunol. 2015, 33:475-504.
9. Schneider C., et al. The human IgG anti-carbohydrate repertoire exhibits a universal architecture and contains specificity for microbial attachment sites. Sci. Transl. Med. 2015, 7:269ra261.
10. Galili U., et al. A unique natural human IgG antibody with anti-alpha-galactosyl specificity. J. Exp. Med. 1984, 160:1519-1531.
11. Galili U., et al. Human natural anti-alpha-galactosyl IgG. II. The specific recognition of alpha (1-3)-linked galactose residues. J. Exp. Med. 1985, 162:573-582.
12. Galili U., et al. The human natural anti-Gal IgG. III. The subtlety of immune tolerance in man as demonstrated by crossreactivity between natural anti-Gal and anti-B antibodies. J. Exp. Med. 1987, 165:693-704.
13. Avrameas S. Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'. Immunol. Today 1991, 12:154-159.
14. Galili U., et al. Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human flora. Infect. Immun. 1988, 56:1730-1737.
15. Bovin N.V. Natural antibodies to glycans. Biochemistry (Moscow) 2013, 78:786-797.
16. Landsteiner K. The Specificity of Serological Reactions 1900, Courier Dover Publications.
17. Springer G.F., Horton R.E. Blood group isoantibody stimulation in man by feeding blood group-active bacteria. J. Clin. Invest. 1969, 48:1280-1291.
18. Briles D.E., et al. Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 streptococcus pneumoniae. J. Exp. Med. 1981, 153:694-705.
19. Ochsenbein A.F., et al. Control of early viral and bacterial distribution and disease by natural antibodies. Science 1999, 286:2156-2159.
20. Navin T.R., et al. Effect of immunoglobulin M from normal human serum on Leishmania donovani promastigote agglutination, complement-mediated killing, and phagocytosis by human monocytes. Infect. Immun. 1989, 57:1343-1346.
21. Ochsenbein A.F., Zinkernagel R.M. Natural antibodies and complement link innate and acquired immunity. Immunol. Today 2000, 21:624-630.
22. Pleass R.J., et al. Immunoglobulin M: restrainer of inflammation and mediator of evasion by Plasmodium falciparum malaria. Trends Parasitol. 2015, 10.1016/j.pt.2015.09.007.
23. Thurnheer M.C., et al. B1 cells contribute to serum IgM, but not to intestinal IgA, production in gnotobiotic Ig allotype chimeric mice. J. Immunol. 2003, 170:4564-4571.
24. Kawahara T., et al. Peritoneal cavity B cells are precursors of splenic IgM natural antibody-producing cells. J. Immunol. 2003, 171:5406-5414.
25. Benatuil L., et al. Ig knock-in mice producing anti-carbohydrate antibodies: breakthrough of B cells producing low affinity anti-self antibodies. J. Immunol. 2008, 180:3839-3848.
26. Wang L., et al. Human anti-Gal heavy chain genes. Preferential use of VH3 and the presence of somatic mutations. J. Immunol. 1995, 155:1276-1285.
27. Oyelaran O., et al. Profiling human serum antibodies with a carbohydrate antigen microarray. J. Proteome Res. 2009, 8:4301-4310.
28. Bishop J.R., Gagneux P. Evolution of carbohydrate antigens - microbial forces shaping host glycomes?. Glycobiology 2007, 17:23R-34R.
29. Thall A.D., et al. alpha 1,3-Galactosyltransferase-deficient mice produce naturally occurring cytotoxic anti-Gal antibodies. Transplant. Proc. 1996, 28:556-557.
30. Diswall M., et al. Antigen-binding specificity of anti-alphaGal reagents determined by solid-phase glycolipid-binding assays. A complete lack of alphaGal glycolipid reactivity in alpha1,3GalT-KO pig small intestine. Xenotransplantation 2011, 18:28-39.
31. Milland J., et al. Carbohydrate residues downstream of the terminal Galalpha(1,3)Gal epitope modulate the specificity of xenoreactive antibodies. Immunol. Cell Biol. 2007, 85:623-632.
32. Milland J., et al. The molecular basis for galalpha(1,3)gal expression in animals with a deletion of the alpha1,3galactosyltransferase gene. J. Immunol. 2006, 176:2448-2454.
33. Macher B.A., Galili U. The Galalpha1,3Galbeta1,4GlcNAc-R (alpha-Gal) epitope: a carbohydrate of unique evolution and clinical relevance. Biochim. Biophys. Acta 2008, 1780:75-88.
34. Guo H., et al. Molecular analysis of the O-antigen gene cluster of Escherichia coli O86:B7 and characterization of the chain length determinant gene (wzz). Appl. Environ. Microbiol. 2005, 71:7995-8001.
35. Hennet T. The galactosyltransferase family. Cell. Mol. Life Sci. 2002, 59:1081-1095.
36. Doenz U., et al. Anti-Galalpha1-3Gal IgM/IgG antibody levels in infants: do they have a clinical relevance in pediatric xenotransplantation?. J. Heart Lung Transplant. 2000, 19:1108-1113.
37. LaTemple D.C., Galili U. Adult and neonatal anti-Gal response in knock-out mice for alpha1,3galactosyltransferase. Xenotransplantation 1998, 5:191-196.
38. Hamadeh R.M., et al. Anti-alpha-galactosyl immunoglobulin A (IgA), IgG, and IgM in human secretions. Clin. Diagn. Lab. Immunol. 1995, 2:125-131.
39. Lundell A.C., et al. Infant B cell memory differentiation and early gut bacterial colonization. J. Immunol. 2012, 188:4315-4322.
40. Yatsunenko T., et al. Human gut microbiome viewed across age and geography. Nature 2012, 486:222-227.
41. De Filippo C., et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:14691-14696.
42. Buffie C.G., Pamer E.G. Microbiota-mediated colonization resistance against intestinal pathogens. Nat. Rev. Immunol. 2013, 13:790-801.
43. Fan X., et al. Donor-specific B-cell tolerance after ABO-incompatible infant heart transplantation. Nat. Med. 2004, 10:1227-1233.
44. Cox F.E. History of the discovery of the malaria parasites and their vectors. Parasites Vectors 2010, 3:5.
45. Macedo C.S., et al. Overlooked post-translational modifications of proteins in Plasmodium falciparum: N- and O-glycosylation - a review. Mem. Inst. Oswaldo Cruz 2010, 105:949-956.
46. Ramasamy R., Reese R.T. A role for carbohydrate moieties in the immune response to malaria. J. Immunol. 1985, 134:1952-1955.
47. Ramasamy R., Reese R.T. Terminal galactose residues and the antigenicity of Plasmodium falciparum glycoproteins. Mol. Biochem. Parasitol. 1986, 19:91-101.
48. Ramasamy R., et al. Antibodies and Plasmodium falciparum merozoites. Trends Parasitol. 2001, 17:194-197.
49. Ramasamy R., Field M.C. Terminal galactosylation of glycoconjugates in Plasmodium falciparum asexual blood stages and Trypanosoma brucei bloodstream trypomastigotes. Exp. Parasitol. 2012, 130:314-320.
50. Nardin E.H., et al. Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax. J. Exp. Med. 1982, 156:20-30.
51. Pingel S., et al. Purification and characterization of an alpha-galactosyltransferase from Trypanosoma brucei. Biochem. J. 1999, 338:545-551.
52. Zamze S.E., et al. Structural characterization of the asparagine-linked oligosaccharides from Trypanosoma brucei type II and type III variant surface glycoproteins. J. Biol. Chem. 1991, 266:20244-20261.
53. Almeida I.C., et al. Lytic anti-alpha-galactosyl antibodies from patients with chronic Chagas disease recognize novel O-linked oligosaccharides on mucin-like glycosyl-phosphatidylinositol-anchored glycoproteins of Trypanosoma cruzi. Biochem. J. 1994, 304:793-802.
54. Couto A.S., et al. The N-linked carbohydrate chain of the 85-kilodalton glycoprotein from Trypanosoma cruzi trypomastigotes contains sialyl, fucosyl and galactosyl (alpha 1-3)galactose units. Mol. Biochem. Parasitol. 1990, 39:101-107.
55. Avila J.L., et al. Immunogenic Gal alpha 1-3Gal carbohydrate epitopes are present on pathogenic American Trypanosoma and Leishmania. J. Immunol. 1989, 142:2828-2834.
56. Towbin H., et al. Circulating antibodies to mouse laminin in Chagas disease, American cutaneous leishmaniasis, and normal individuals recognize terminal galactosyl(alpha 1-3)-galactose epitopes. J. Exp. Med. 1987, 166:419-432.
57. Avila J.L., Rojas M. A galactosyl(alpha 1-3)mannose epitope on phospholipids of Leishmania mexicana and L. braziliensis is recognized by trypanosomatid-infected human sera. J. Clin. Microbiol. 1990, 28:1530-1537.
58. Bates P.A. Transmission of Leishmania metacyclic promastigotes by phlebotomine sand flies. Int. J. Parasitol. 2007, 37:1097-1106.
59. Avila J.L. alpha-Galactosyl-bearing epitopes as potent immunogens in Chagas disease and leishmaniasis. Subcell. Biochem. 1999, 32:173-213.
60. McConville M.J., et al. The glycoinositol phospholipids of Leishmania mexicana promastigotes. Evidence for the presence of three distinct pathways of glycolipid biosynthesis. J. Biol. Chem. 1993, 268:15595-15604.
61. McConville M.J., et al. Structure of the lipophosphoglycan from Leishmania major. J. Biol. Chem. 1990, 265:19611-19623.
62. Bretana A., et al. American Leishmania spp. and Trypanosoma cruzi: galactosyl alpha(1-3) galactose epitope localization by colloidal gold immunocytochemistry and lectin cytochemistry. Exp. Parasitol. 1992, 74:27-37.
63. Ding J.W., et al. Hyperacute rejection by anti-Gal IgG1, IgG2a, and IgG2b is dependent on complement and Fc-gamma receptors. J. Immunol. 2008, 180:261-268.
64. Yooseph S., et al. Stool microbiota composition is associated with the prospective risk of Plasmodium falciparum infection. BMC Genomics 2015, 16:631.
65. Posekany K.J., et al. Induction of cytolytic anti-Gal antibodies in alpha-1,3-galactosyltransferase gene knockout mice by oral inoculation with Escherichia coli O86:B7 bacteria. Infect. Immun. 2002, 70:6215-6222.
66. Abrahamsohn I.A., Silva W.D. Antibody dependent cell-mediated cytotoxicity against Trypanosoma cruzi. Parasitology 1977, 75:317-323.
67. Almeida I.C., et al. Complement-mediated lysis of Trypanosoma cruzi trypomastigotes by human anti-alpha-galactosyl antibodies. J. Immunol. 1991, 146:2394-2400.
68. Gazzinelli R.T., et al. Direct lysis of Trypanosoma cruzi: a novel effector mechanism of protection mediated by human anti-gal antibodies. Parasite Immunol. 1991, 13:345-356.
69. Souto-Padron T., et al. Distribution of alpha-galactosyl-containing epitopes on Trypanosoma cruzi trypomastigote and amastigote forms from infected Vero cells detected by Chagasic antibodies. J. Eukaryot. Microbiol. 1994, 41:47-54.
70. Pereira-Chioccola V.L., et al. Mucin-like molecules form a negatively charged coat that protects Trypanosoma cruzi trypomastigotes from killing by human anti-alpha-galactosyl antibodies. J. Cell Sci. 2000, 113:1299-1307.
71. Van Valen F. A new evolutionary law. Evol. Theor. 1973, 1:1-30.
72. Samuelson J., et al. The diversity of dolichol-linked precursors to Asn-linked glycans likely results from secondary loss of sets of glycosyltransferases. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:1548-1553.
73. Bushkin G.G., et al. Suggestive evidence for Darwinian selection against asparagine-linked glycans of Plasmodium falciparum and Toxoplasma gondii. Eukaryot. Cell 2010, 9:228-241.
74. Ramasamy R. Studies on glycoproteins in the human malaria parasite Plasmodium falciparum-lectin binding properties and the possible carbohydrate-protein linkage. Immunol. Cell Biol. 1987, 65:147-152.
75. Cabezas-Cruz A., et al. Regulation of the immune response to alpha-Gal and vector-borne disease. Trends Parasitol. 2015, 31:470-476.
76. McConville M.J., Bacic A. A family of glycoinositol phospholipids from Leishmania major. Isolation, characterization, and antigenicity. J. Biol. Chem. 1989, 264:757-766.
77. Sloand E.M., et al. Correction of the PNH defect by GPI-anchored protein transfer. Blood 1998, 92:4439-4445.
78. Dunn D.E., et al. A knock-out model of paroxysmal nocturnal hemoglobinuria: Pig-a(-) hematopoiesis is reconstituted following intercellular transfer of GPI-anchored proteins. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:7938-7943.
79. Rifkin M.R., Landsberger F.R. Trypanosome variant surface glycoprotein transfer to target membranes: a model for the pathogenesis of trypanosomiasis. Proc. Natl. Acad. Sci. U.S.A. 1990, 87:801-805.
80. Astronomo R.D., Burton D.R. Carbohydrate vaccines: developing sweet solutions to sticky situations?. Nat. Rev. Drug Discov. 2010, 9:308-324.
81. Davitt C.J., Lavelle E.C. Delivery strategies to enhance oral vaccination against enteric infections. Adv. Drug Deliv. Rev. 2015, 91:52-69.
82. Cobb B.A., et al. Polysaccharide processing and presentation by the MHCII pathway. Cell 2004, 117:677-687.
83. Abdel-Motal U.M., et al. Mechanism for increased immunogenicity of vaccines that form in vivo immune complexes with the natural anti-Gal antibody. Vaccine 2009, 27:3072-3082.
84. Hackett J. Use of Salmonella for heterologous gene expression and vaccine delivery systems. Curr. Opin. Biotechnol. 1993, 4:611-615.
85. Holmgren J., Czerkinsky C. Cholera as a model for research on mucosal immunity and development of oral vaccines. Curr. Opin. Immunol. 1992, 4:387-391.
86. Zhang Z.H., et al. Oral vaccination of mice against rodent malaria with recombinant Lactococcus lactis expressing MSP-1(19). World J. Gastroenterol. 2005, 11:6975-6980.
87. Eckburg P.B., et al. Diversity of the human intestinal microbial flora. Science 2005, 308:1635-1638.
88. Varki A., et al. Essentials of Glycobiology 2009, Cold Spring Harbor Laboratory Press. 2nd edn.
89. Pradel G., et al. Proteoglycans mediate malaria sporozoite targeting to the liver. Mol. Microbiol. 2002, 45:637-651.
90. Frevert U., et al. Cell surface glycosaminoglycans are not obligatory for Plasmodium berghei sporozoite invasion in vitro. Mol. Biochem. Parasitol. 1996, 76:257-266.
91. Christiansen D., et al. Humans lack iGb3 due to the absence of functional iGb3-synthase: implications for NKT cell development and transplantation. PLoS Biol. 2008, 6:e172.
92. Galili U., Swanson K. Gene sequences suggest inactivation of alpha-1,3-galactosyltransferase in catarrhines after the divergence of apes from monkeys. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:7401-7404.
93. Hayakawa T., et al. Alu-mediated inactivation of the human CMP-N-acetylneuraminic acid hydroxylase gene. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:11399-11404.
94. Tangvoranuntakul P., et al. Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:12045-12050.
95. Varki A., Gagneux P. Human-specific evolution of sialic acid targets: explaining the malignant malaria mystery?. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:14739-14740.